treatment efficacy of artesunate-amodiaquine and...

Treatment efficacy of artesunate-amodiaquine and

prevalence of Plasmodium falciparum drug

resistance markers in Zanzibar, 2002-2017

May 2019

Aung Paing Soe Master in Global Heath, 30 credits (Spring 2019)

International Maternal and Child Health (IMCH)

Department of Women’s and Children’s Health

Supervisors: Dr. Soorej Jose Puthoopparambil and Prof. Mats Målqvist

IMCH, Uppsala

External Supervisors: Dr. Ulrika Morris and Prof. Anders Björkman

Molecular, Cell and Tumor Department, Biomedicum, Karolinska Institutet,

Stockholm

(9739 words)

UPPSALA UNIVERSITET Resistance Markers to Artesunate and Amodiaquine

Contents Abstract ....................................................................................................................................................... 1

Acknowledgements ..................................................................................................................................... 2

Abbreviations and Glossary ....................................................................................................................... 3

1. Introduction ............................................................................................................................................. 4

1.1 Global Malaria burden ..................................................................................................................... 4

1.2 Malaria Elimination in History ....................................................................................................... 5

1.3 Genetic Studies in Malaria ............................................................................................................... 7

1.4 Study Context: Zanzibar .................................................................................................................. 8

1.5 Malaria Epidemiology in Zanzibar ................................................................................................. 9

1.6 Rationale of the Study .................................................................................................................... 10

2. Methodology .......................................................................................................................................... 11

2.1 Study Design .................................................................................................................................... 11

2.2 Molecular Analysis ......................................................................................................................... 15

2.3 Brief Descriptions of Previous Studies .......................................................................................... 16

2.4 Statistical Analysis .......................................................................................................................... 17

2.5 Ethical Considerations ................................................................................................................... 17

2.6 Clinical Trial Registrations ............................................................................................................ 18

3. Results .................................................................................................................................................... 19

3.1 Study Participants ........................................................................................................................... 19

3.2 Treatment Outcome ........................................................................................................................ 21

3.3 Molecular Analysis ......................................................................................................................... 22

4. Discussion .............................................................................................................................................. 26

4.1 Efficacy of Artesunate-Amodiaquine ............................................................................................ 26

4.2 Single Nucleotide Polymorphisms ................................................................................................. 26

4.2.1 Haplotypes ................................................................................................................................. 27

4.3 Generalizability ............................................................................................................................... 27

4.4 Study Limitations ............................................................................................................................ 28

5. Conclusion ............................................................................................................................................. 29

References .................................................................................................................................................. 30

Annex ......................................................................................................................................................... 36


Page 1 of 42

Abstract

Introduction: Emergence of resistance to artemisinin-based combination therapy (ACT) is a

major threat to combat Plasmodium falciparum malaria. Regular therapeutic studies to monitor

treatment efficacy is essential, and genotyping of molecular makers is useful for mapping

development and spread of resistance.

Aims: The study aims are to assess efficacy of artesunate-amodiquine (ASAQ) and prevalence of

molecular markers of drug resistance in Zanzibar in 2017.

Methods: Treatment efficacy of the clinical trial conducted in 2017 was compared with efficacies

in 2002 and 2005. A total of 142 samples were genotyped for single nucleotide polymorphisms

(SNPs) in the P. falciparum chloroquine resistance transporter gene (pfcrt) gene, the P. falciparum

multi drug resistance 1 (pfmdr1) gene, and in the P. falciparum Kelch 13 (PfK13) propeller region.

Prevalence of SNPs were assessed during the period 2002-2017.

Results: Cure rate was 100% in 2017, compared to 94% and 96%, in 2002-2003 and 2005,

respectively. Day 3 fever clearance rate were also high 93% (2002-3), 99% (2005) and 98% (2017)

in all studies. Prevalence of pfcrt 76T, pfmdr1 86Y, 184Y and 1246Y and pfmdr1 (86Y, 184Y and

1246Y) YYY haplotypes were significantly decreased between 2002-3 and 2017 (p < 0.001). No

SNP in the PfK13 gene related to artemisinin resistance was identified.

Conclusion: Efficacy of ASAQ remains high after fourteen years as first-line treatment, despite

the wide-scale use of ASAQ, and there is no evidence of selection of resistance markers in

Zanzibar. Continuous monitoring of drug efficacy and resistance markers is recommended.

Keywords: Plasmodium falciparum, Artesunate-amodiaquine, Therapeutic efficacy studies,

Molecular surveillance, Antimalarial drug resistance

Total: 246 words


Page 2 of 42

Acknowledgements

Firstly, I would like to express my gratitude to Andreas for introducing to KI team to implement

both my internship and master project. Secondly, my sincere thanks to Ulrika, Soorej, Mats and

Anders who had encouraged and supported me to complete this final milestone in “Global

Health” journey. Thirdly, my special thanks to Ulrika who helped a lot not only to finish

molecular works but also guidance throughout this project. And I will definitely remember

friendly colleagues and lunch time chit chat in the sun at Biomedicum. Also, I am grateful to my

peers in Uppsala for giving constructive feedback to improve the draft.

Last but not least, my humble thanks to all who had implemented all trials and surveys included

in this project. And I would like to extend my thanks especially to Mwinyi Msellem and the

Zanzibar Malaria Elimination Team.


Page 3 of 42

Abbreviations and Glossary

ACT Artemisinin-based combination therapy

AL Artemether-lumefantrine

AQ Amodiaquine

AS Artesunate

ASAQ Artesunate plus Amodiaquine

CI Confidence Interval

CQ Chloroquine

DBS Dry Blood Spot

DEAQ Desethylamodiaquine

DNA Deoxyribonucleic acid

IRS Indoor Residual Spray

ITN Insecticide Treated Net

PfK13 gene Plasmodium falciparum Kelch 13 gene

LLIN Long-lasting Insecticidal Net

mRDT Malaria Rapid Diagnostic Test

nPCR Nested PCR

PCR Polymerase Chain Reaction

Pfcrt Plasmodium falciparum chloroquine resistance transporter gene

Pfmdr1 Plasmodium falciparum Multi-Drug Resistance 1 gene

qPCR Quantitative PCR

RFLP Restriction Fragment Length Polymorphism

SNP Single Nucleotide Polymorphism

SP Sulfadoxine–pyrimethamine

WHO World Health Organization

WWARN Worldwide Antimalarial Resistance Network

ZAMEP Zanzibar Malaria Elimination Programme

ZMCP Zanzibar Malaria Control Programme


Page 4 of 42

1. Introduction

1.1 Global Malaria burden

Malaria is a life-threatening disease caused by Plasmodium parasites carried through the bite of

infected female Anopheles mosquitos [1]. There were five human malaria parasites including

plasmodium falciparum, plasmodium vivax, plasmodium malariae, plasmodium ovale and

plasmodium knowlesi [1]. Among them P. falciparum and P. vivax imposed the greatest threat to

humans. In 2017, P. falciparum accounted for estimated 99.7%, 62.8%, 69%, 71.9% in the WHO

African Region, WHO region of South-East Asia, Eastern Mediterranean and the Western Pacific,

respectively. P. vivax represented 74.1% cases in the WHO Region of the Americas [2].

Malaria is a major public health issue and remains one of leading causes of morbidity and mortality

especially in low and middle income countries [2]. According to world malaria report 2018, an

estimated 219 million cases of malaria was reported globally, of which estimated 92% (200

million) of the cases were from WHO African Region [2]. The remaining 5% and 2% of cases

were from the WHO South-East Asia Region and the WHO Eastern Mediterranean Region,

respectively [2]. Globally, an estimation of 435,000 malaria deaths occurred in 2017, of which

61% (266,000) deaths were in children aged under 5 years. [2].

The earlier world malaria report estimated that 86% (212 out of 247 million) of malaria episodes

and 91% (801 000 out of 881 000) of malaria deaths occurred in the Africa Region in 2006 [3].

Therefore, the Africa Region remains suffering from a high burden area of malaria. Malaria burden

prevents the countries from economic growth; Gallup and Sachs reported that a 10% reduction in

malaria index was associated with 0.3% rise in annual growth [4]. Recent data showed that global

malaria incidence rates decreased from 72 cases per 1000 population at risk in 2010, to 59 per

1000 in 2017, 80% of cases were concentrated only in 10 countries from sub-Saharan Africa and

one country in Asia, India [2]. Hence, there are countries in Africa that are changing strategies

from malaria control to elimination after significant reductions in malaria cases and deaths since

2003-4 [2,3]. However, there was heterogeneity of malaria endemicity in between and within the

certain countries in the region.

Malaria control is defined as the “Reduction of disease incidence, prevalence, morbidity or

mortality to a locally acceptable level as a result of deliberate efforts. Continued interventions are

required to sustain control” [5]. Malaria elimination is defined as “Interruption of local

transmission (reduction to zero incidence of indigenous cases) of a specified malaria parasite in

a defined geographical area as a result of deliberate activities. Continued measures to prevent re-

establishment of transmission are required” [5]. The previous world malaria report stated that

there are 4 out of 41 countries in Africa - Eritrea, Rwanda, Sao Tome and Principe, and Zanzibar


Page 5 of 42

(United Republic of Tanzania) – had the highest impact of malaria control in the region, where

malaria burden was reduced 50% or more, between 2000 and 2006-7 with higher population access

to antimalarial drugs, insecticidal nets, and high coverage of indoor residual spraying (IRS) [3].

Consistently, Björkman et al. reported that malaria burden in Zanzibar has started to decreased

with first deployment of artemisinin based combination therapy (ACT) in 2003 together with free

universal distribution of long lasting insecticidal nets (LLIN) in 2005 and IRS in 2007 [6].

Therefore, maintaining the impact of reduction is beneficial not only to Zanzibar but also other

countries in the world.

1.2 Malaria Elimination in History

1.2.1 Wars and Development of Malaria Control Tools

During the World War I (1914 -1918), the third relentless foe that weakened both allied and axis

military forces, was malaria [7]. Available published data and military records indicate that at least

1.5 million soldiers were estimated to be infected with malaria, and case fatality was ranging from

0.2 -5.0% within a four-year period [7]. In the First World War, Quinine, the oldest antimalarial

drug, was mainstay treatment for malaria [7]. During World War II (1939 – 1945), the United

States Army did extensive research to combat malaria at home and fronts [8]. As an outcome of

this effort, dichloro-diphenyl-trichloroethane (DDT) and Chloroquine were developed which in

turn revolutionized malaria control and even framed the global malaria eradication strategy after

the end of the Second World War [8].

1.2.2 Global Malaria Eradication Program

The World Health Assembly held in Mexico approved the Global Malaria Eradication Program

(GMEP) in 1955 [9]. By employing DDT mainly as malaria vector control tool, which killed

specifically indoor resting adult mosquitos, led to raise high hopes among national malaria control

programs to eliminate malaria globally [9]. During the period 1955 to 1987, in total of 22 countries

and 2 territories were certified as malaria-free by WHO, but the GMEP was not successful in

reaching its goal to eliminate malaria globally owing to the development of drug resistance and

insecticidal resistance [9–11]. The lessons learnt from GMEP can be summarized as the

ingredients for a successful public health program are not only sustainable financial and political

support, but also effective malaria surveillance and continuous research, active community

participation, and flexibility of the program to cope with changing disease epidemiology [9].


Page 6 of 42

1.2.3 Early Development of Resistance

Although IRS with DDT was initially a successful vector control intervention, early signs of the

mosquito vector resistance to DDT was first reported in Greece in 1951 [12]. Not only did the

vector development resistance to insecticides, the malaria parasite also developed resistance to the

main antimalarial of choice, resulting in major challenges in the GMEP [9]. According to WHO

definition, malaria drug resistance is defined as “the ability of a parasite strain to survive and/or

multiply despite the administration and absorption of a drug given in doses equal to or higher

than usually recommended but within the limits of tolerance of the subject” [5]. Quinine resistance

was first reported from the railway construction site in the Brazilian Amazon in 1910 and later

reported from Thailand, Asia in 1987 [13,14]. Moreover, the emergence of P. falciparum

chloroquine resistance imposed a new burden to the elimination of malaria; resistance was

confirmed along the Cambodia-Thailand border and in Cambodia by 1960 [15]. Payne reported

that wide-scale use of Chloroquine added in table salt led to faster development of chloroquine

resistance to P. falciparum [16].

1.2.4 Development of the Nobel Prize Winning Drug

After the emergence of resistance to Quinine, bark from the cinchona tree as early as in 1910, and

another resistance to synthetic compound, Chloroquine in 1960, urgent development of new

alternative potent drug to fight against malaria was crucial [13,16]. Antimalarials drugs have been

used in the world for centuries. The therapeutic use of cinchona appeared in 17th century in the

West but in the East, the alternative, qinghaosu, was used in Chinese herbal medicine even earlier

[17]. The exploration of Chinese herbs with antimalarial activity was started in 1969 and

artemisinin was discovered in 1979 [18]. Professor Youyou Tu later reported that the hope in

search of a new drug lay in a quote mentioned in “A Handbook of Prescriptions for Emergencies”

by Ge Hong (284–346 CE) [18]. The quote stated that the use of qinghao as “A handful of qinghao

immersed with 2 liters of water, wring out the juice and drink it all” [18].

1.2.5 Artemisinin-based Combination Therapy

In the mid-1990s, the artemisinin-based combination therapies (ACT) were introduced to ensure

the maximum therapeutic life to replace the failing drug such as chloroquine and sulfadoxine–

pyrimethamine (SP) [19]. WHO recommended to use ACT “to reduce the number of parasites

during the first 3 days of treatment (reduction of parasite biomass), while the role of the partner

drug is to eliminate the remaining parasites (cure)” [20]. The combination of short acting

artemisinin derivatives with long acting partner drug aids the rapid resolution of clinical

symptoms, for instance, fever and fast reduction of parasite biomass and prevent development of

gametocytes [20].


Page 7 of 42

1.2.6 Prevention of ACT Resistance

The widespread use of ACTs has significantly contributed to reduced malaria transmission and a

reduction in malaria related deaths over the last two decades [21]. Unfortunately, emergence of

resistance to artemisinin-based combination therapy was first reported in western Cambodia and

Thai-Cambodia border in 2008 and 2009 [22,23]. Therefore, continuous surveillance of drug

resistance plays an important role in hindering the spread of artemisinin resistance and maintaining

the therapeutic efficacy of ACTs [24].

1.3 Genetic Studies in Malaria

Molecular studies of malaria has certain role not only in diagnosis of malaria by PCR methods but

also monitoring of specific genetic markers that were related to drug resistance [25].

1.3.1 Molecular Markers and Drug Resistance

A review on malaria drug resistance reported that single nucleotide polymorphisms (SNPs) in the

P. falciparum multidrug resistance 1 (pfmdr1) gene and P. falciparum chloroquine resistance

transporter (pfcrt) were associated with decreased sensitivity to quinine [26]. Moreover, both in

vitro and in vivo studies, have shown that the pfcrt 76T and the pfmdr1 86Y SNPs are associated

with resistance to chloroquine and amodiaquine [27–34]. Amodiaquine and its active metabolites

desethylamodiaquine (DEAQ) has similar mechanism to chloroquine and the pfmdr1 86Y, 184Y,

and 1246Y haplotype has been found to be involved in resistance/treatment failures of

amodiaquine (DEAQ) [35,36].

In addition, mutations in the P. falciparum Kelch 13 (PfK13) propeller region have been associated

with delayed parasite clearance after treatment with artemisinin [37]. The combined analysis of

PfK13-propeller sequence polymorphisms drew the conclusion that the most common African

allele (PfK13 A578S) was not associated with artemisinin resistance, and there was no evidence

of artemisinin resistance outside South East Asia and China to date [37,38]. In 2012, a single

synonymous SNP (PfK13 C469C) in 5 out of 23 isolates was reported in Fukayosi, Tanzania which

has no association with drug resistance (parasite clearance half-life is less than 5.5 hour) [37].

Recent study in mainland Tanzania found seven non-synonymous PfK13 mutations (L463S,

G496S, M476I, V510M, E556K, M562T and E602D), none of which were associated with day 3

parasitemia [39]. The most prevalent PfK13 alleles (F446I, R539T, I543T, P574L and C580Y)

that are associated with artemisinin resistance (delayed parasite clearance) in South East Asia

region have not been detected in the sub-Saharan Africa to date [37,40]. In contrast, PfK13 plays

an important role in determining artemisinin resistance in South East Asia [41].


Page 8 of 42

1.4 Study Context: Zanzibar

Geographically, Zanzibar is an archipelago consisting of several islands located in Indian Ocean,

adjacent to mainland Tanzania (Figure 1). Administratively, Zanzibar is a semi-autonomous

region of Tanzania composed of two main islands with a population of approximately 1.3 million

people [42]. According to the 2012 census report, the population in Unguja, the largest island, was

about 900,000 and in Pemba over 400,000 people [42]. In 2017, the world bank’s poverty

assessment of Zanzibar showed that there was the steady improvement in urban areas, and

although overall the poverty rate remained as 30.4%, the rate in Pemba island was increased by

6.9% from 48.5% in 2010 to 55.4% in 2015 [43]. The interrelatedness of malaria and poverty has

been recognized for long time, yet the causality is multiple and complex. [44]. Even though the

causality between malaria and poverty is fairly debatable, a review article revealed that there was

direct or indirect association between socio-economic status and uptake of preventive and

treatment measures [45]. Since the 2008-9 fiscal year, the health care budget in Zanzibar has

increased throughout the years, however, out of pocket spending is still 30% of the total household

expenditure [46].

1.4.1 GMEP Era (1955–1969)

Zanzibar was one of the participating countries in the Global Malaria Elimination Program [9].

Owing to effective vector control interventions, there was significant reduction of malaria

prevalence from as high as 74.2 % before 1960 to as low as 6.3 % in the GMEP era [11]. However,

suppression of malaria to very low levels, did not imply that malaria was no longer a threat, instead

malaria resurged to critical levels by the end of 1990 [11,47].

Figure 1. A geographical map of Mainland Tanzania and Zanzibar. (Source: Malaria

Indicator Survey Report 2017 [48])


Page 9 of 42

1.5 Malaria Epidemiology in Zanzibar

1.5.1 Malaria Epidemiology and Control Measures in Zanzibar

According to WHO, uncomplicated malaria patient is defined as “a patient who presents with

symptoms of malaria and a positive parasitological test (microscopy or RDT) but with no features

of severe malaria” [20]. The first line ACT for uncomplicated falciparum malaria has been

artesunate-amodiaquine (ASAQ) since 2003 [20]. In contrast, the first ACT in mainland Tanzania

is Artemether-Lumefantrine since January 2007 [49]. The wide-scale deployment of ACT, free of

charge for all ages at public health facilities, together with strengthened vector control with long

lasting insecticidal nets (LLIN) and IRS has contributed to the remarkable reduction of malaria in

Zanzibar [6].

The predominant human malaria parasite is P. falciparum in both mainland and Zanzibar [50].

The findings of entomological surveillance showed that there was the major shift in primary vector

population – Anopheles gambiae (95%) to An. arabiensis (89%) - after wide-scale use of IRS and

LLIN in Zanzibar between 2005 and 2010 [6,50]. In addition to that, human biting rates per person

night was also decreased 98% (12.44 to 0.27) between 2002-3 and 2010 when An. arabiensis

becoming the predominant vector with outdoor biting behavior [6]. In 2015, coverage of the two

key vector control interventions for indoor biting malaria such as IRS and ITNs were

approximately 80% in Zanzibar [6].

1.5.2 Progress During MDGs (1990-2015) and Beyond

In September 2000, heads of state and government from 189 countries around the world came

together to United Nations Headquarter in New York to sign United Nations Millennium

Declaration at General Assembly [51]. The Millennium Development Goals (MDGs) involve the

global effort to alleviate poverty and improve health and well-being of all individuals [52]. There

were in total of 8 goals, 21 targets and 60 indicators for measuring progress between 1990 and

2015 [53]. Among them, MDG Goal 4. “To reduce child mortality” and Goal 6. “To combat

HIV/AIDS, malaria, and other diseases” are directly linked to reduction of malaria burden [52].

The MDGs progress reports has shown that the MDG Goal 4 the Under 5 mortality rate (U5MR)

declined from 202 per 1,000 live births in 1990, to 101 per 1,000 in 2005, and declined again to

79 per 1,000 in 2010 in Zanzibar, where the communicable diseases including malaria remains the

leading cause of under 5 mortality [54]. The continuation of progress in malaria control has been

proven that the community malaria prevalence was reduced from 10.3% to 0.43%, and under 5

mortality from 1.01% to 0.36% between 2003 and 2015 [6]. The main reductions occurred after

malaria control activities were initiated, with the endorsement of ASAQ as first line antimalarial

to treat P. falciparum in 2003 [6]. The microscopy/RDT positivity rate was reduced significantly


Page 10 of 42

(a mean reduction of 94.2%) between 2002 and 2015 [6]. Annual decreasing of positivity rate from

2003 to 2015 can be found in Appendix 1. Moreover, the estimation of annual parasite incidence

(APIs) was reduced from 3.6 to 2.0 per 1000 inhabitants between 2003 and 2008. Zanzibar is

approaching to become a “very low transmission” area with lower APIs (<5 cases per 1000

population) and malaria prevalence (> 0 but < 1%) according the malaria elimination framework

by WHO [55]. Therefore, the implementation strategies of the Zanzibar Malaria Control Program

(ZMCP) were adapted to a pre-elimination setting [6]. The deployment of implementation

strategies over the past decade in Zanzibar can be found in the Appendix 2. In August 2013,

ZMCP changed its name to the Zanzibar Malaria Elimination Program (ZAMEP) [56]. At the end

of MDGs era, sustainable development agenda were developed based on achievement of MDGs

[57]. In 2015, world leaders adopted 17 Sustainable development goals (SDGs) to further

improvement of inequalities, alleviate poverty and combat climate change [58]. SDGs has 17

goals, 169 targets and 230 indicators in which SDG goal 3 “Ensure healthy lives and promote

well-being for all at all ages” is related mainly to health [59]. SDG target 3.3 is to “fight

communicable diseases” in which SDG indicator 3.3.3 is to reduce malaria incidence to 9 or fewer

cases per 1,000 population by 2030 [53,60]. Despite the achievement has been made in the MDGs

era, Zanzibar still have final milestones to reach in the SGDs era until achieving malaria

elimination.

1.6 Rationale of the Study

Resistance to artemisinin-based combination therapies, first line antimalarial drugs to treat P.

falciparum malaria, is one of the greatest challenges in both malaria control and elimination [2].

In order to combat the growing resistance, WHO recommends conducting therapeutic efficacy

(TES) studies at regular intervals in all endemicity (high-moderate-low) to update and validate in

vivo therapeutic drug efficacy [40]. TES studies involved initial treatment with ACT accompanied

by follow-up period of 28 to 42 days [40]. In addition, genotyping of molecular markers has been

a useful tools for monitoring drug resistance overtime and to track development and spread of

resistance alleles in malaria parasites [24]. Since 2003, ASAQ has been the first line treatment for

uncomplicated P. falciparum malaria in Zanzibar. Therefore, continuous monitoring of drug

efficacy is crucial to track the development of resistance markers after fourteen years deployment

of ASAQ. This study will assess the efficacy of ASAQ combined with single low-dose primaquine

(PQ) and the prevalence of SNPs that are associated with artesunate and amodiaquine resistance

in a clinical trial conducted in 2017 in Zanzibar. The findings of genotyping of specific markers

including pfcrt 76T, pfmdr1 86Y, Y184 and 1246Y associated with tolerance/resistance to


Page 11 of 42

amodiaquine, and SNPs in the PfK13 propeller domain associated with resistance to artemisinin,

will be compared with previous studies conducted during the period 2002-2013.

1.6.1 Main Research Question

What is the efficacy of ASAQ and the prevalence of molecular markers associated with resistance

to both artesunate and amodiaquine, after fourteen years of use as first-line treatment?

1.6.2 Additional Aims and Objectives

1. To assess the treatment outcome in 2017, in comparison with treatment outcomes in 2002-3

and 2005

2. To assess trends in molecular markers of amodiaquine resistance in 2002-3, 2005, 2010, 2013

and 2017 studies

3. To examine the prevalence of SNPs in PfK13 propeller domain in 2017 compared to 2013

2. Methodology

2.1 Study Design

The samples analyzed in this study were collected during a one-armed clinical trial with the aim

to assess the efficacy of ASAQ given together with single low dose PQ (0.25mg/Kg). Evans

described the single-arm design as “…the simplest trial design where a sample of individuals with

the targeted medical condition is given the experimental therapy and then followed over time to

observe their response” [61]. In this single-arm trial, all enrolled individuals were given same

aforementioned antimalarial drugs with a 28-day follow-up period to assess the clinical and

parasitological response. Adequate clinical and parasitological response (ACPR) defined as the

“absence of parasitemia on day 28, irrespective of axillary temperature, in patients” [55]. During

the follow-up period, clinical and laboratory examinations were conducted on scheduled visits on

days 1, 2 and 3 and after treatment visits on days 7, 14, 21 and 28. According to the clinical and

laboratory assessments, the patients were classified into therapeutic failure (early or late) or

adequate therapeutic response group. The study protocol was based on the WHO guidelines for

surveillance of antimalarial drug efficacy [24].

2.1.1 Study Sites

The clinical trial involved 14 primary health care (PHC) facilities in three regions including

Micheweni on Pemba Island, and Bububu and Uzini on Unguja Island (Figure 2). These 14 PHCs

served as “Satellite Sites” where participants were screened for malaria using Rapid Diagnostic

Test (mRDT). Only uncomplicated P. falciparum positive malaria patients diagnosed by mRDT,

and those who meet the inclusion criteria (see below) were eligible for the study. Patients were


Page 12 of 42

referred to the “Recruitment Sites” to be enrolled in the study. The “Recruitment Site” was set up

with microscope, haemaque machine for hemoglobin measurements, and well-trained technicians.

The responsive candidates were then oriented to the study protocol.

Figure 2. A geographical map of Zanzibar indicating study sites in circles. The study

involved three districts - West and Central on Unguja Island and Micheweni on Pemba Island.

Source: Barnes 2018 [62]

2.1.2 Study Population

In total of 9062 patients of all ages presenting at the satellite study sites with sign and symptoms

compatible with uncomplicated P. falciparum malaria were screened and 146 patients were

enrolled in the study. Informed consent was obtained before the study; consent forms were signed

prior to study enrollment.

2.1.3 Timing and Duration of the Study

The study was conducted for six months from April to October 2017.

2.1.4 Sample size Calculation

Sample size was calculated for an efficacy rate of 95% with 95% CIs and margin of error <5%.

To achieve this precision, at least 90 patients were required where attrition rate was set for 20%

of patient enrolled.


Page 13 of 42

2.1.5 Participant Selection

Uncomplicated P. falciparum positive malaria cases were recruited according to following

inclusion and exclusion criteria.

Inclusion Criteria

• Age 3 months and above;

• P. falciparum infection detected by mRDT and confirmed by microscopy;

• Presence of P. falciparum malaria asexual parasitemia (any level, regardless of high

or low parasitemia)

• Presence of axillary ≥37.5 °C or history of fever during the past 48 hours

• Ability to swallow oral medication;

• Ability and willingness to comply with the study protocol for the duration of the

study and to comply with the study visit schedule; and

• Informed consent from the patient or from a parent or guardian in the case of

children.

Exclusion Criteria

• Presence of general danger signs in children aged under 5 years or signs of severe

falciparum malaria according to the definitions of WHO (Appendix 3);

• Mono-infection with a Plasmodium species other than P. falciparum detected by

microscopy;

• Presence of febrile conditions other than malaria (e.g. measles, acute lower

respiratory tract infection, severe diarrhea with dehydration) or other known

underlying chronic or severe diseases (e.g. severe malnutrition, cardiac, renal and

hepatic diseases, HIV/AIDS);

• Regular medication, which may interfere with the study drugs; (Appendix 4)

• History of hypersensitivity reactions or contraindications to any of the study

medicines; and

• Pregnancy

Individuals who were excluded from study also received standard health care services. Details

information regarding ethical perspective can be found under “Ethical considerations” section.


Page 14 of 42

2.1.6 Treatment and Follow-up

Artesunate + amodiaquine was administered orally as a fixed dose combination, i.e.

Artesunate/Amodiaquine Winthrop®, prequalified by the WHO, at a dose of approximately 4

mg/kg artesunate + 10mg/kg amodiaquine once daily for 3 consecutive days. PQ was administered

orally, i.e. ® Sanofi Aventis prequalified by the WHO, as a single dose (0.25 mg/kg) together with

the first dose of ASAQ. All doses of antimalarial was administered under direct supervision by a

researcher or clinic staff. The study participants were observed for 30 minutes to monitor any

adverse reactions or vomiting. If the patients vomited within 30 minutes, he/she was re-treated

again and observed for another 30 minutes. Patients who did not tolerate the treatment were given

rescue therapy and withdrawn from the study. Every effort was made to schedule a follow-up visits

for those who failed to return to the study site. A participant had the right to withdraw consent at

any time without losing access to health care services. Detailed information regarding “patient

discontinuation or protocol violation” can be found in the Appendix 5.

2.1.7 Clinical and Laboratory Examination

The following clinical and laboratory examinations were conducted during scheduled visits after

being admitted to the study. The assessment timepoints in relation to following procedures are

mentioned in the Table 1.

Table 1. Laboratory tests and clinical examinations performed during the study.

Day 0 1 2 3 7 14 21 28

Any time

with fever

Treatment + + + +

Blood smear + + + + + + + + +

Hemoglobin + + + + + +

Temperature + + + + + + + + +

Clinical history +

Physical Examination + + + + + + + + +

Filter paper sample + + + + + + + + +


Page 15 of 42

Physical Examination – A complete medical history and demographic information and contact

details were taken at baseline.

Measuring Body Weight – To assess the nutrition status, and for determining treatment dose

(number of tablets).

Body Temperature – axillary temperature was measured for all the participants.

Microscopic Blood Examination – Giemsa-stained thick films were taken by qualified

microscopists for asexual and gametocyte counts. Malaria species was identified at screening on

day 0 to confirm adherence in line with the inclusion and exclusion criteria.

Filter Paper Blood Samples – Two to three drops of blood (50-100µL) were collected from finger

pricks on 3MM (Whatman) filter paper for genotyping of malaria parasites.

Pregnancy Test for women of reproductive age (15 -49 years) – woman found to be pregnant at

screening were excluded from this study. Pregnant women in the first trimester were treated with

oral quinine 10 mg/kg body weight, 8 hourly for 7 days. Pregnant women in the second and third

trimester received artesunate 4 mg/kg + amodiaquine 10 mg/kg treatment once daily for 3 days

according to national treatment guidelines. During the entire study period, female study

participants of child-bearing age, defined as above (menstruating women above 49 years were also

considered), were encouraged to use barrier methods for contraception, and the possible risks of

the study drugs to the fetus during pregnancy was explained.

Assessment of Hemoglobin Level –Assessment of anemia and to monitor possible adverse effects

of PQ in G6PD deficient patient.

2.2 Molecular Analysis

Molecular analysis regarding the study SNPs were performed to assess the existence of markers

that are related to artesunate + amodiaquine and artemisinin resistance. A total of 142 samples

from Day 0 and another 9 recurrent samples detected by quantitative PCR (qPCR) at Day 28 [62]

were examined in this study. The analysis of SNPs and gene amplifications associated with

tolerance/resistance to ACT was performed according to established protocols at Karolinska

Institutet, Stockholm, Sweden.

The genotyping of the SNPs pfcrt K76T, pfmdr1 N86Y, Y184F and D1246Y were analyzed

according to established nested PCR – restriction fragment length polymorphism (RFLP)

protocols [63]. Firstly, DNA extraction from “Dried Blood Spots” (DBS) collected on filter paper

(3MM; Whatman) was conducted following the Chelex-100 resin (Bio-Rad Laboratory, USA)


Page 16 of 42

extraction protocol (adapted from (Hsiang et al., 2010)) [64]. Then the extracted DNA were run

for nested PCR followed by RFLP [65]. The nest PCR reaction involved 1× Taq polymerase

reaction buffer, 2.5–3 mM magnesium chloride, 0.2 mM dNTP, 0.5–1 μM of each primer and 1.25

units of Taq DNA polymerase (Promega Corporation, USA). The RFLP reactions involved 1 ×

NEBuffer 1/3, 0–1 × BSA and 10 U/reaction of ApoI, Tsp509 I or EcoR V restriction enzymes

following manufacturers’ instruction (New England Biolabs, UK). Positive and negative controls

(3D7, Dd2 and 7G8) and a no template control were included in each PCR-RFLP procedure.

Extracted DNA was stored at -20 ºC until use. Finally, the product of PCR-RFLP were run by gel-

electrophoresis on 2–2.5% agarose gel stained with GelRed. Then the visualization of the

genotypes was done under UV transillumination (GelDoc 2000, BioRad, HerculesW, CA, USA).

PCR-RFLP method was used to determine the existence of polymorphisms using restriction

enzymes, for instance, point mutation in genotype pfmdr1 codon 86 resulted in changing the amino

acid from wild-type (Asparagine) to mutant (Tyrosine) [66]. However, PCR-RFLP gel

electrophoresis results can either be wild-type alone, mutant alone or both, i.e., mixed infection.

A mixed infection was defined if the PCR-RFLP results contain both undigested and digested PCR

amplicons. The PCR-RFLP results were reviewed by two independent reviewers. Any inconsistent

findings were evaluated by third person for confirmation. Regarding analysis of haplotypes, all

isolates presenting as a mixed infection for more than one SNP were excluded from the analysis.

In addition, polymorphisms in the 850bp fragment of the kelch 13 propeller domain were analyzed

by nested PCR amplification with Q5 high-fidelity polymerase (New England Biolabs, UK),

follow by bidirectional direct Sanger sequencing of the PCR amplicon (Ariey et al., 2014) [67].

2.3 Brief Descriptions of Previous Studies

The two previous clinical in vivo trials were conducted in 2003/3 [68] and 2005 (unpublished).

They were both open labelled, randomized two-arm studies comparing in vivo efficacy of ASAQ

and artemether-lumefantrine in children (age ≤5 years) with uncomplicated P. falciparum malaria

(2000-200 000 parasites/µl). Study procedures embracing the standard ethical requirements in two

previous studies were similar to those in 2017 study. The molecular analyses were also similar

except the sequencing of PfK13 gene which were only performed for 2017 study samples. Baseline

characteristics of the study participants are described in Table 2.

In addition, samples collected in 2010 and 2013 were included in the trend analysis of SNPs. The

study conducted in 2010 was a health facility-based survey conducted in twelve primary health

care facilities, six each in North A (Unguja Island) and Micheweni (Pemba Island) districts. In

total of 121 RDT positive samples collected from febrile patients were genotyped for SNPs in

pfcrt and pfmdr1 [69]. The samples from 2013 were also collected from febrile patients attending


Page 17 of 42

health facilities. mRDT positive fever patients at PHC facilities were recruited during January–

July 2013 in the same two sentinel study districts as above. Total 113 patients were included for

genotyping of SNPs in 2013 [65].

2.4 Statistical Analysis

Data from the clinical trials were entered by two independent data clerks in Microsoft Excel sheets

and cleaned using GSPro. Statistical analysis was performed in Stata. 95% Confidence Intervals

(CIs) were calculated for proportions, fever clearance rate, parasite clearance rate by microscopy,

proportions of patients cured on Day 28, as well as for geometrical mean parasite densities on

Days 1-3. Trend analysis of SNPs 2002-2017 was performed by comparing the frequencies of

genotypes in-between the study years by Chi square test or fisher exact test for smaller frequencies.

Statistical significance was defined as p < 0.05. The sequencing output of PfK13 was analyzed by

using Sequencher 5.1 software to identify polymorphisms.

2.5 Ethical Considerations

2.5.1 Informed Consent – Consent forms were translated from English into Swahili, and then

explained to the patient, parent or guardian. Details about the trial and its benefits and potential

risks were explained. Participants over 18 years of age were asked to sign a consent form after any

questions had been answered; written assent form was taken from children under the age of 18. If

the patient was illiterate, a literate witness was asked to sign; if possible, the signatory with no

connection to the research team was selected by the participant. Consent statement for the

pregnancy test was also required for female participants of child-bearing age who were sexually

active.

2.5.2 Confidentiality - All information regarding patients remained confidential and shared only

by the study team. Unique identifiers were used for computer-based data entry and blood samples.

In all cases, the principal investigator checked that screening forms, the case report form, and the

completed identification code list were kept in locked files.

2.5.3 Free Health Care - throughout the follow-ups, health care services were provided to the

study patients presented with any illness related to malaria regardless of treatment outcome. Any

person who decided not to participate or who did not meet the criteria were referred to the health

facility staff. If a patient was withdrawn from the study before he/she has completed the full course

of the treatment, the clinician provided all necessary arrangements to receive the full dose of the

medicine.

2.5.4 Compensation – Transportation costs for all visits to the health center were covered and

reimbursed in this study.


Page 18 of 42

2.5.5 Ethical Approvals – All studies involved in this analysis were conducted in accordance with

the principles stated in the latest version of the Declaration of Helsinki and Good Clinical Practice

(World Medical Association Declaration of Helsinki, 2013) [70]. For the present study (2017),

ethical approval was obtained from the Zanzibar Medical Research and Ethics Committee

[ZAMREC/0001/January/2016] and the Zanzibar Food and Drugs Board

[No.ZFDB/M.M:B:L:Z/16]. Ethical approval for molecular work at Karolinska Institutet was

granted by the Regional Ethics Committee in Stockholm, Sweden [2013/836-32].

2.6 Clinical Trial Registrations

ClinicalTrials.gov Identifiers: NCT03764527 (study performed 2002/3), CT03768908 (study

performed 2005), NCT01002066 (study performed 2010) and NCT03773536 (present study

2017).


Page 19 of 42

3. Results

3.1 Study Participants

A total of 9062 febrile patients were screened at the fourteen health centers from May to September

2017. Out of 233 mRDT positive candidates, 146 met all inclusion criteria and were enrolled at

the three “Recruitment Sites”.

Baseline patient characteristics are presented in Table 2, along with the data from the previous

clinical trials in 2002/3 [68] and 2005 (Unpublished). Despite differences in patients age the

geometrical means of the parasite density at study enrollment were quite similar. There was high

compliance to the study protocol, and only two patients were withdrawn from the study due to

“repeated vomiting on day 1” and “itching on day 3” and another two were lost to follow-up due

to “long travel distance” and “travel to mainland Tanzania during follow-up”. Hence a total of

142/146 (97.3%) fulfilled the study follow-up to Day 28. Below study flow chart describes the

number of individuals screened, enrolled and included in final analysis (Figure 3).

9062 screened

233 mRDT positive

97.4 % (8829/9062) mRDT negative

146 enrolled

144 completed

follow-ups

2.7 % (4/146) lost to follow-up &

minor side effects

37.3 % (87/233) do not met

inclusion criteria

Figure 3 – Study Flow Chart


Page 20 of 42

Table 2. Patient characteristics at enrollment who received artesunate-amodiaquine (ASAQ) for treatment of malaria for uncomplicated P

falciparum malaria infections

Characteristics 2002/3 2005 2010 20131 2017

Screened 2097 2076 20423 ND 9062

Enrolled 207 177 121 113 146

Sex, no. of patients

Male 104 81 65 ND 101

Female 103 94 56 ND 45

Age, months or years, median

(range)2 24 (4 –72) months 28 (4 – 60) months 12 (0 - 92) years

21.5 (1.5 - 50)

years 16 (2 - 56) years

Parasite count, parasites/mL,

geometric mean (range)

19,731 (2000–

198,440)

20890 (2000–

176,000) 7699 (6 - 782400) ND

7610,46 (55-

304000)

Temperature, _C, arithmetic mean ±

SD 38.7 ± 1.2 37.8 ± 1.2 38.3 ± 1.4 ND 37.8 ± 1.4

Hemoglobin level, g/dL, arithmetic

mean ± SD 8.5 ± 1.6 9.2 ± 1.4 ND ND 11.7 ± 2.2

1Baseline data not collected for samples collected in 2013. 2Only under 5 children were recruited in 2002/3 and 2005 studies


Page 21 of 42

3.2 Treatment Outcome

Parasite clearance rate up to Day 3 by microscopy was similar in all three clinical trials (2002-3,

2005 and 2017) (Figure 4). In 2017study, only one patient remained malaria positive by

microscopy by day 3, apart from that all participants were negative up to Day 28 in contrast to the

findings in 2002/3 and 2005 (Table 3). The cure rates were 94% (95% CI 89.4-96.5), 96% (95%

CI 91.7-98.3) and 100% (95% CI 97.4-100.0) for 2002-3, 2005 and 2017 studies, respectively.

The cure rate in 2017 is higher than that of PCR adjusted cure rate (358/378); (94.7%; 95% CI

91.9-96.7) for 2002/3 and 2005 combined (p = <0.001). The total number of recurrent parasitemia

– new infections during 28 days of follow-up – were 44 (22%), 16 (9%) and zero (0%) in 2002/3,

2005 and 2017 respectively.

Figure 4. Mean parasite clearance by microscopy from Day 0 to Day 3 – representing mean

parasite density determined by microscopy comparing clearance in 2002-3, 2005 and 2017 in

Log scale. Note: There is no parasitemia at day 3 in 2005 study.

1

10

100

1000

10000

100000

D0 D1 D2 D3

Mea

n p

aras

ie d

enis

ty (

Par

asit

es/µ

L)

2002-3 2005 2017


Page 22 of 42

Table 3. ASAQ treatment outcome after 28 days follow-up

(i) Number completed follow-up as per protocol/number enrolled

(ii) Number of recrudescence after PCR correction

(iii) MSP1 and GLURP genotyping were not done since there was no positive case by microscopy on day-

28 in 2017

The fever clearance rates were also high (<37.5 ºC by Day 3) in all studies - 93% in 2002/3, 99%

in 2005, and 98% in 2017. Hemoglobin levels were higher at enrollment (Day 0) in 2017 than in

2002/3 and 2005 (Table 2). The average decline by Day 7 after treatment with ASAQ + PQ was

mean 1.1 g/dL (-3.3 to 6.6) in 2017, compared to mean 0.2 g/dL (-3.4 to 4.1) after treatment with

ASAQ alone in 2002-3.

3.3 Molecular Analysis

The prevalence of the SNPs in pfcrt K76T, pfmdr1 N86Y, Y184F and D1246Y (2002/3 - 2017)are

presented in Figure 5. Overall, the decreasing trend of isolates associated with amodiaquine were

identified. There was significant decline in frequencies of pfcrt 76T (98% to 4.9%, p < 0.001),

pfmdr1 86Y (86.7% to 2.1%, p < 0.001), pfmdr1 Y184 (99.5% to 61.3%, p = 0.005, and pfmdr1

1246Y (36% to 1.4%, p < 0.001) between 2002-3 and 2017. In the present study, the enrolled

patients who had overnight travelled to mainland Tanzania was 21% (30/144). Human migration

between Zanzibar island and Mainland could increase the importation of P. falciparum infection

from Tanzania where AL is prescribed as first-line antimalarial drug. Therefore, present of travel

history assuming imported malaria infections are compared with locally acquired cases in Zanzibar

(Table 4). However, parasite genotype profiles are similar and there was no significant association

with regards to the travel history in all alleles.

Year of study Total patients

(i)

Positive

Day 3

Parasite

recrudesce (ii)

Recurrent

new infection

2002/3 206/208 1 (0.5%) 13 (6%) 44 (22%)

2005 172/177 0 7 (4%) 16 (9%)

2017 142/146 1 (1%) 0 (0%) (iii) 0 (0%) (iii)


Page 23 of 42

Figure 5. Molecular genotyping of single nucleotide polymorphisms in P. falciparum

infections. This bar chart showing the frequency of polymorphisms associated with amodiaquine

resistance. The solid (black) represents the resistance alleles, pattern (dotted) - mixed infection

and white – wild-type, respectively. The error bars represent the 95% confidence interval of the

proportions of resistance alleles (either alone or mixed infections). The total number of genotyped

samples are shown in the bracket next to study year.

Table 4. Proportions of P. falciparum infections with the genotypes/associated with

tolerance/resistance to amodiaquine (Pfcrt and Pfmrd1 genes) in 2017 according to travel

history to mainland Tanzania

2017 Pfcrt n/N (%) Pfmdr1 n/N (%)

76T 86Y 184Y 1246Y YYY

Yes travel 2/30 (6.6%) 1/30 (3.3%) 20/30 (66%) 0/30 (0.0%) N/A

No travel 5/114 (4.4%) 2/114 (1.8%) 67/114 (58.7%) 2/114 (1.8%) N/A

All 7/144 (4.9%) 3/144 (2.1%) 97/144 (67.4%) 2/144 (1.4%) N/A

(1) All mixed infections (i.e. mutant + wildtype) were also counted as resistance alleles.

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

20

02

-3 (

199

)

20

05

(1

74)

20

10

(1

05)

20

13

(9

4)

20

17

(1

42)

20

02

-3 (

196

)

20

05

(1

71)

20

10

(1

10)

20

13

(9

8)

20

17

(1

42)

20

02

-3 (

198

)

20

05

(1

73)

20

10

(1

12)

20

13

(9

4)

20

17

(1

42)

20

02

-3 (

200

)

20

05

(1

75)

20

10

(1

05)

20

13

(9

4)

20

17

(1

44)

pfcrt K76T pfmdr1 N86Y pfmdr1 Y184F pfmdr1 D1246Y

Fre

qu

ency

%

76T; 86Y; Y184; 1246Y Mixed K76; N86; 184F; D1246


Page 24 of 42

A total of nine samples positive by qPCR on Day 28 were also processed for nested PCR to

examine the status of SNPs. However, these samples have shown very low (<1 p/µl) parasite

density by quantitative PCR, and they were all consistently negative in the nested PCR used for

genotyping SNPs. Therefore, the Day 28 samples were not successfully genotyped.

The pfmdr1 YYY and YYD are the most frequent haplotypes in 2002-3, in contrast, the NYD and

NFD haplotypes were most frequent in 2017. There was zero YYY and only three YYD in 2017

study. There was significant decline of YYY (p < 0.001) and YYD (p <0.001) between 2002-3

and 2017 (Figure 6).

Figure 6. Haplotypes shift from YYY to FDN between 2002 & 2017, representing the

frequencies of pfmdr1 haplotypes. (N86Y, Y184F, and D1246Y). Fisher exact test was

performed to compare the frequencies between all years. Asterisk (*) and (**) indicate p value

below 0.05 and 0.001 respectively.

A PfK13 pilot study conducted in 2013 identified no SNPs in the PfK13 propeller region in

Zanzibar, yet the finding still needs validation due to small sample size (N=34) (unpublished).

However, regarding genotyping of PfK13 gene, 98% (139 out of 142) samples were successfully

sequenced in 2017. Among them, 5 (3.6%) samples had the previously reported synonymous SNP

cysteine to cysteine at amino acid position 469 (CYS 469 CYS) which was previously reported

from Fukayosai, Tanzania in 2012 [37]. One additional synonymous SNP serine to serine at amino

acid position 477 (SER 477 SER) was also identified in a single (0.7%) sample Table 5. In 2017,

only 1 out of 6 isolates reported history of travelling to mainland, Tanzania in the past one month.

Moreover, the association between PfK13 and presence of travel history cannot be proven due to

small sample size. Nevertheless, the SNPs identified in 2017 study are not associated with

artemisinin resistance [37].

0

10

20

30

40

50

60

70

80

90

100

YYY YYD YFD NYD NFY NFD

freq

uec

y %

of

Pfm

dr1

Ha

plo

typ

es

Figure 4. Haplotypes shift from YYY to FDN between

2002 & 2017

2002 2005 2010 2013 2017

** **

** **

**

*

* *

*

*


Page 25 of 42

Table 5. Representing PfK13 single nucleotide polymorphisms identified in 2017 according to

travel history to mainland Tanzania

Study

Site

Age (years

=yr or

month=mth)

Sex

(M/F)

Travel

(Y/N) PfK13 SNP1

Previous

Reported

SNP (Y/N)

Bububu 22yr F N Synonymous SNP: CYS 469 CYS Y

Bububu 6 yr M N Synonymous SNP: CYS 469 CYS Y

Uzini 7 yr M Y Synonymous SNP: CYS 469 CYS Y

Bububu 21 mth F N Synonymous SNP: CYS 469 CYS Y

Bububu 15 yr M N Synonymous SNP: CYS 469 CYS Y

Bububu 41 yr F N Synonymous SNP: SER 477 SER N

1Synonymous mutation within PfK13 alleles C469C was previously reported in Fukayosi,

Tanzania in 2012 [37].


Page 26 of 42

4. Discussion

Zanzibar is one of the countries in the Africa Region with the most remarkable decrease in both

malaria morbidity and mortality since 2005 [6,50]. To achieve malaria elimination, maintaining

the drug efficacy and prevention of development of resistance is critical. The aim of this study is

to assess the drug efficacy of ASAQ and track the development of molecular markers that are

known to be associated with amodiaquine and artesunate resistance. The following sections

discussed the evidence provided as the result of this study in relation to the drug efficacy of ASAQ

and polymorphisms associated with resistance to amodiaquine and artesunate.

4.1 Efficacy of Artesunate-Amodiaquine

Efficacy studies conducted in Zanzibar (2002-3, 2005 and 2017) consistently showed that the first

line ACT (ASAQ) treatment for uncomplicated P. falciparum malaria remains effective. Malaria

diagnosis by microscopy is the conventional tool to monitor drug resistance in therapeutic efficacy

studies, and revisions of national malaria treatment guideline can be considered if day 3

parasitemia and day 28 cure rates are more than 10% and less than 90%, respectively [71].

Microscopic examination of malaria parasites showed that parasitemia on day 3 were as low as

0.5%, 0% and 1%, and cure rates on day 28 remains as high as 94%, 96% and 100% in 2002-3,

2005 and 2017 respectively. In addition, the proportion of recurrent infection on day 28 (after PCR

correction) decreased during the period from 2002-3 to 2017. Findings regarding treatment

efficacy could provide as an evidence to maintain ASAQ as a first line treatment in Zanzibar.

4.2 Single Nucleotide Polymorphisms

Polymorphisms in pfcrt and pfmdr1gene have been associated with reduced sensitivity to ASAQ

and AL, yet the characteristic of these alleles are not fully understood [72]. The selection of pfcrt

76T, pfmdr1 86Y, 184Y and 1246Y alleles have been associated with reduce sensitivity to ASAQ,

whilst in reverse, selection of wild types alleles are related to reduced sensitivity in AL [29–

31,33,35,73]. Hence, pfmdr1 86N, 184F and 1246D alleles were found to be associated with high

proportion of treatment failure in Tanzania where AL was the first line drug to treat falciparum

malaria [36]. Similarly, a study conducted in Burkina Faso reported that there was significant

increase in pfcrt 76K and decreased in pfcrt 76T after AL treatment whereas increased in pfcrt

76T and decreased in pfcrt 76K after ASAQ treatment [73]. Regarding pfmdr1 N86Y alleles, 86Y

has been associated with increased with ASAQ treatment failure, but the evidence is less

convincing for pfmdr1 Y184F [73].

On the one hand, the mechanism of higher selection of wild types in this study SNPs - pfcrt 76K,

pfmdr1 86N, 184F and 1246D alleles - are not fully understood. On the other hand, continuous

wide-scale use of ASAQ is more likely to select mutant type due to presence of sustain drug


Page 27 of 42

pressure at population level [27,29,30,35,36]. However, in 2012, Froberg et al. reported the first

observation of decreased prevalence of SNPs that were associated with ASAQ resistance in

Zanzibar and suggested three possible underlying causes of selecting pfcrt 76K, pfmdr1 86N and

1246D alleles were genetic dilution caused by imported cases form mainland Tanzania, selection

by artesunate per se, and fitness cost of the parasite itself. [74]. Parasite fitness seems to have

advantage over selection of circulating resistant parasites [75]. The prevalence of mutants pfcrt

76T and pfmdr1 86Y found to be decreased in low transmission areas when drug pressure is

diminishing [65,75,76]. However, information regarding mediating factors of resistance

polymorphisms on parasite fitness is not known sufficiently [76]. In 2015, Morris et al. also

reported that significant further decline in pfcrt 76T and pfmdr1 86Y alleles in Zanzibar [65].

Current study (2017) has shown further reductions in markers associated with tolerance and

resistance to ASAQ since the last time report in 2015. The molecular findings of 2017 study are

consistent with two previous studies, hence, continuous monitoring of genetic changes in SNPs

have strong implication for shaping malaria treatment policy in Zanzibar.

4.2.1 Haplotypes

In the study, pfmdr1 (86Y, 184Y, 1246Y) haplotypes YYY and YYD are the most frequent in

2002-3, but interestingly, NYD and NFD haplotypes were most frequent in 2017. NFD haplotypes

were associated with reduced sensitivity to AL [77]. There was only three YYD and zero YYY

haplotypes that are otherwise known to be the risk factor for treatment failure in patients treated

with ASAQ in African settings [35,77,78]. There was a significant decline of YYY (p < 0.001)

and YYD (p <0.001) between 2002-3 and 2017. A study conducted in Western Kenya reported

that when the drug pressure of AQ is decreased, there was significant increase in selection of

pfmdr1 and pfcrt wild type alleles within three year period (between 2008 – 2010) of replacing

AQ with ACT as a first line treatment [79]. This provides additional evidence that ASAQ remains

an effective first line treatment in Zanzibar.

4.3 Generalizability

This study was a follow-up study to monitor efficacy of local first line ACT in Zanzibar with

adaptation of WHO TES guideline to surveillance of artemisinin resistance. Findings of this paper

may contribute to reaching the elimination target in Zanzibar by ensuring the effectiveness of

ASAQ plus single low dose PQ. The aim is to eliminate local malaria transmission by 2023,

according to the Zanzibar Malaria Elimination Programme. Moreover, this study can contribute to

pooled analysis of resistance data initiated by such as “Worldwide Antimalarial Resistance

Network” (WWARN) and WHO world artemisinin status reports. Although the findings in this

study are specific to the Zanzibar setting, and are not generalizable to other settings with varied


Page 28 of 42

malaria endemicities, and applicable to other ACTs, the study protocol involving satellite sites and

recruitment centers in order to achieve a large enough sample size to power a clinical trial can be

applicable to other low-transmission settings.

4.4 Study Limitations

4.4.1 Limitation of Study Designs

The original studies involved in this analysis are three clinical trials and two surveys. Two surveys

conducted in 2010 and 2013 were health facility based, providing a snap-shot measurement of the

prevalence of drug resistance markers, and did not assess treatment efficacy. Regarding three

clinical trials, follow-up period in 2017 study was 28 days, whilst it was 42 days for the two

previous studies (2002-3 and 2005). Although WHO recommends 28 days follow-up period for

antimalarials including amodiaquine - which have elimination half-lives of less than 7 days, longer

duration of follow-up up to 42 days in clinical trials is beneficial to evaluate the true cure rate [24].

The study conducted in Zanzibar (2002-3) reported that high proportion of recrudescence after

day-28 follow-up [68]. Additionally, laboratory analysis to differentiate re-infection or

recrudescence was not done for day-28 in 2017 study since there was no parasite positivity by

microscopy on day-28.

4.4.2 Participants Characteristics

Despite the patient’s demographic and clinical information such as age, sex, history of fever,

hemoglobin level, treatment history, parasite and gametocyte carriage and parasite density are

available for clinical trials, there was no comprehensive data for two surveys conducted in 2010

and 2013. Therefore, no complete data was available for comparison of fever clearance,

parasitemia and hemoglobin level assessments for all studies.

4.4.3 Molecular Methods

Overall, the limitation of highly sensitive PCR is risk of contamination which can lead to false

positive results. However, even highly sensitivity PCR can still give negative results if the parasite

density approaches to the detection limit. For such very low density sub-microscopic infection can

also give inconsistent results owing to the lower reproducibility [80]. Moreover, the sensitivity of

RFLP assay is low to detect mixed infection. Regarding running of gel-electrophoresis, it is

moderately time consuming and requires minor adjustments to get a better visualization.

Repetition is unavoidable until the DNA bands are clear enough for identification of interest.


Page 29 of 42

5. Conclusion

Despite the wide-scale use of ASAQ as first-line drug to treat uncomplicated P. falciparum

malaria, efficacy remains high after fourteen years of first deployment in 2003. The molecular

markers associated with ASAQ resistance - SNPs pfcrt 76T, pfmdr1 86Y, 184Y and 1246Y alleles

and pfmdr1 (86Y, 184Y and 1246Y) YYY haplotypes were significantly decreased between 2002-

3 and 2017. Although two synonymous SNPS in the PfK13 gene (five CYS469CYS and one

SER477SER isolates) were identified, these SNPs have not been associated with artemisinin

resistance. Continuous monitoring of drug efficacy and resistance markers is warranted to track

the development and characteristics of artemisinin resistance in Zanzibar.


Page 30 of 42

References

1. World Health Organization. malaria [Internet]. 2018 [cited 2019 May 11]. Available from: https://www.who.int/ith/ITH_chapter_7.pdf

2. World Health Organization. World malaria report 2018 [Internet]. 2018 p. 210. Available from: https://www.who.int/malaria/publications/world-malaria-report-2018/en/

3. World Health Organization, UNICEF, editors. Management of the child with a serious infection or severe malnutrition: guidelines for care at the first-referral level in developing countries. Geneva: Dept. of Child and Adolescent Health and Development, World Health Organization : UNICEF; 2000. 162 p.

4. Gallup JL, Sachs JD. The Economic Burden of Malaria. American Society of Tropical Medicine and Hygiene; 2001.

5. World Health Organization. WHO malaria terminology [Internet]. 2018. Available from: https://www.who.int/malaria/publications/atoz/malaria-terminology/en/

6. Björkman A, Shakely D, Ali AS, Morris U, Mkali H, Abbas AK, et al. From high to low malaria transmission in Zanzibar—challenges and opportunities to achieve elimination. BMC Med. 2019 Jan 22;17(1):14.

7. Brabin BJ. Malaria’s contribution to World War One – the unexpected adversary. Malar J. 2014 Dec;13(1):497.

8. Hays CW. The United States Army and malaria control in World War II. Parassitologia. 2000 Jun;42(1–2):47–52.

9. Nájera JA, González-Silva M, Alonso PL. Some Lessons for the Future from the Global Malaria Eradication Programme (1955–1969). PLoS Med. 2011 Jan 25;8(1).

10. World Health Organization. Eliminating malaria [Internet]. 2016. Available from: https://www.who.int/malaria/publications/atoz/eliminating-malaria/en/

11. World Health Organization. From malaria control to malaria elimination: a manual for elimination scenario planning [Internet]. World Health Organization W, editor. Geneva, Switzerland: Global Malaria Programme, World Health Organization; 2014. 53 p. Available from: https://www.who.int/malaria/publications/atoz/9789241507028/en/

12. Livadas GA, Georgopoulos G. Development of resistance to DDT by Anopheles sacharovi in Greece. Bull World Health Organ. 1953;8(4):497–511.

13. da Silva AFC, Benchimol JL. Malaria and Quinine Resistance: A Medical and Scientific Issue between Brazil and Germany (1907–19). Med Hist. 2014 Jan;58(1):1–26.

14. Pukrittayakamee S, Supanaranond W, Looareesuwan S, Vanijanonta S, White NJ. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg. 1994 Jun;88(3):324–7.

15. Payne D. Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today. 1988 Apr 1;4(4):112–5.

16. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today. 1987 Aug 1;3(8):241–6.


Page 31 of 42

17. Packard RM. The Origins of Antimalarial-Drug Resistance. N Engl J Med [Internet]. 2014 Jul 31 [cited 2019 Apr 27];371(5):397–9. Available from: https://doi.org/10.1056/NEJMp1403340

18. Tu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011 Oct 11;17:1217–20.

19. Cui L, Su X. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009 Oct;7(8):999–1013.

20. World Health Organization. Guidelines for the treatment of malaria (Third Edition) [Internet]. 2015. Available from: https://www.who.int/malaria/publications/atoz/9789241549127/en/

21. Jagoe G, Amuasi JH. Saving lives through improved use of ACTs. Lancet Glob Health. 2015 Dec 1;3(12):e727–8.

22. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of Artemisinin-Resistant Malaria in Western Cambodia. N Engl J Med. 2008 Dec 11;359(24):2619–20.

23. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin Resistance in Plasmodium falciparum Malaria. N Engl J Med. 2009 Jul 30;361(5):455–67.

24. World Health Organization. Methods for surveillance of antimalarial drug efficacy [Internet]. 2009 [cited 2019 Apr 28]. Available from: https://www.who.int/malaria/publications/atoz/9789241597531/en/

25. GHOLIZADEH S, NASERI KARIMI N, ZAKERI S, DINPARAST DJADID N. The Role of Molecular Techniques on Malaria Control and Elimination Programs in Iran: A Review Article. Iran J Parasitol. 2018;13(2):161–71.

26. Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. Am J Trop Med Hyg. 2015 Sep 2;93(3 Suppl):57–68.

27. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology. 1997 Mar;114 ( Pt 3):205–11.

28. Sidhu ABS, Verdier-Pinard D, Fidock DA. Chloroquine Resistance in Plasmodium falciparum Malaria Parasites Conferred by pfcrt Mutations. Science. 2002 Oct 4;298(5591):210–3.

29. Lakshmanan V, Bray PG, Verdier-Pinard D, Johnson DJ, Horrocks P, Muhle RA, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J. 2005 Jul 6;24(13):2294–305.

30. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006 Jul;6(4):309–14.

31. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A Molecular Marker for Chloroquine-Resistant Falciparum Malaria. 2009.

32. Picot S, Olliaro P, Monbrison F de, Bienvenu A-L, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J. 2009 Dec;8(1):89.


Page 32 of 42

33. Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in Uganda. Antimicrob Agents Chemother. 2010 Mar;54(3):1200–6.

34. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014 Oct;91(4):833–43.

35. Holmgren G, Hamrin J, Svärd J, Mårtensson A, Gil JP, Björkman A. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2007 Sep;7(5):562–9.

36. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al. Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria. Antimicrob Agents Chemother. 2007 Mar 1;51(3):991–7.

37. WWARN. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. BMC Med [Internet]. 2019 Jan 17 [cited 2019 May 1];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335805/

38. Ménard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med. 2016 Jun 23;374(25):2453–64.

39. Kakolwa MA, Mahende MK, Ishengoma DS, Mandara CI, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018 Oct 17;17.

40. World Health Organization. Artemisinin resistance and artemisinin-based combination therapy efficacy [Internet]. 2018 [cited 2019 May 1]. Available from: https://apps.who.int/iris/handle/10665/274362

41. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015 Apr;15(4):415–21.

42. National Bureau of Statistics. 2012 Population and housing census [Internet]. 2012. Available from: http://catalog.ihsn.org/index.php/catalog/4618

43. Belghith NBH, De Boisseson PMA. Zanzibar poverty assessment. The World Bank; 2017 Oct p. 1–118. Report No.: 120689.

44. Teklehaimanot and Paola Mejia A. Malaria and Poverty. Ann N Y Acad Sci. 2008 Jul 25;1136(1):32–7.

45. Worrall E, Basu S, Hanson K. Is malaria a disease of poverty? A review of the literature. Trop Med Int Health. 2005;10(10):1047–59.

46. UNICEF. Health Budget Brief Zanzibar 2018 [Internet]. 2018 [cited 2019 Apr 27]. Available from: https://www.unicef.org/esaro/UNICEF-Tanzania-Zanzibar-2018-Health-Budget-Brief-revised.pdf


Page 33 of 42

47. Smith DL, Cohen JM, Moonen B, Tatem AJ, Sabot OJ, Ali A, et al. Infectious disease. Solving the Sisyphean problem of malaria in Zanzibar. Science. 2011 Jun 17;332(6036):1384–5.

48. Ministry of Health. Malaria Indicator Survey 2017 [Internet]. 2017 [cited 2019 Apr 28]. Available from: https://www.dhsprogram.com/pubs/pdf/MIS31/MIS31.pdf

49. World Health Organization. National Guidelines for Malaria Diagnosis and Treatment : Tanzania [Internet]. World Health Organization; 2005 [cited 2019 Apr 20]. Available from: http://apps.who.int/medicinedocs/documents/s19271en/s19271en.pdf

50. Ministry of Health CD Gender, Elderly and Children-MoHCDGEC/Tanzania Mainland, Ministry of Health - MoH/Zanzibar, National Bureau of Statistics - NBS/Tanzania, Office of Chief Government Statistician - OCGS/Zanzibar, ICF. Tanzania Demographic and Health Survey and Malaria Indicator Survey 2015-2016 [Internet]. Dar es Salaam, Tanzania: MoHCDGEC, MoH, NBS, OCGS, and ICF; 2016. Available from: http://dhsprogram.com/pubs/pdf/FR321/FR321.pdf

51. United Nations. United Nations Millennium Declaration [Internet]. 2000 [cited 2019 May 9]. Available from: https://www.un.org/millennium/declaration/ares552e.htm

52. United Nations. The Millennium Development Goals Report 2015 [Internet]. 2015 [cited 2019 May 1]. Available from: https://www.un.org/en/development/desa/publications/mdg-report-2015.html

53. Official list of MDG indicators [Internet]. 2008 [cited 2019 May 9]. Available from: http://mdgs.un.org/unsd/mdg/Resources/Attach/Indicators/OfficialList2008.pdf

54. United Nations Development Program. Country Report on the Millennium Development Goals 2010 [Internet]. 2011 [cited 2019 Apr 28]. Available from: https://www.un.org/en/development/desa/publications/millennium-development-goals-report-2010.html

55. World Health Organization, Global Malaria Programme, World Health Organization. A framework for malaria elimination [Internet]. 2017 [cited 2019 May 1]. Available from: https://www.who.int/malaria/publications/atoz/9789241511988/en/

56. Shakely D. Aiming at malaria elimination in Zanzibar. Inst för mikrobiologi, tumör- och cellbiologi / Dept of Microbiology, Tumor and Cell Biology; 2015.

57. Rosa W, editor. Transforming Our World: The 2030 Agenda for Sustainable Development. In: A New Era in Global Health. New York, NY: Springer Publishing Company; 2017.

58. Rosa W, editor. Transforming Our World: The 2030 Agenda for Sustainable Development. In: A New Era in Global Health [Internet]. New York, NY: Springer Publishing Company; 2017 [cited 2019 May 9]. Available from: http://connect.springerpub.com/lookup/doi/10.1891/9780826190123.ap02

59. United Nations. Official List of Proposed SDG Indicators [Internet]. 2016 [cited 2019 May 15]. Available from: https://unstats.un.org/sdgs/indicators/indicators-list/

60. World Health Organization, World Health Organization, Global Malaria Programme. Global technical strategy for malaria, 2016-2030 [Internet]. 2015. Available from: https://www.who.int/malaria/publications/atoz/9789241564991/en/

61. Evans SR. Clinical trial structures. J Exp Stroke Transl Med. 2010 Feb 9;3(1):8–18.


Page 34 of 42

62. Barnes R. Maintained Efficacy of ASAQ after 14 years of use as first- line treatment for P. falciparum malaria in Zanzibar? 2018. 2018;39.

63. Morris U, Khamis M, Aydin-Schmidt B, Abass AK, Msellem MI, Nassor MH, et al. Field deployment of loop-mediated isothermal amplification for centralized mass-screening of asymptomatic malaria in Zanzibar: a pre-elimination setting. Malar J [Internet]. 2015 Dec [cited 2017 Nov 14];14(1). Available from: http://www.malariajournal.com/content/14/1/205

64. Hsiang MS, Lin M, Dokomajilar C, Kemere J, Pilcher CD, Dorsey G, et al. PCR-based pooling of dried blood spots for detection of malaria parasites: optimization and application to a cohort of Ugandan children. J Clin Microbiol. 2010 Oct;48(10):3539–43.

65. Morris U, Xu W, Msellem MI, Schwartz A, Abass A, Shakely D, et al. Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005–2013. Infect Genet Evol. 2015 Jul;33:110–7.

66. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, et al. The pfmdr1 Gene Is Associated with a Multidrug-Resistant Phenotype in Plasmodium falciparum from the Western Border of Thailand. Antimicrob Agents Chemother. 1999 Dec 1;43(12):2943–9.

67. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014 Jan 2;505(7481):50–5.

68. Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of Artesunate Plus Amodiaquine versus That of Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium falciparum Malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005 Oct 15;41(8):1079–86.

69. Morris U, Aydin-Schmidt B, Shakely D, Mårtensson A, Jörnhagen L, Ali AS, et al. Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -assessment of DNA extraction methods and field applicability. Malar J. 2013 Dec;12(1):106.

70. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [Internet]. 2013 [cited 2019 Apr 28]. Available from: https://jamanetwork.com/journals/jama/fullarticle/1760318

71. World Health Organization. Q&A on artemisinin resistance [Internet]. WHO. 2018 [cited 2019 Apr 27]. Available from: http://www.who.int/malaria/media/artemisinin_resistance_qa/en/

72. WWARN. Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine [Internet]. 2014 [cited 2019 May 1]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183414/

73. Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLOS ONE. 2016 Mar 31;11(3):e0151565.

74. Fröberg G, Jörnhagen L, Morris U, Shakely D, Msellem MI, Gil JP, et al. Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar. Malar J. 2012 Dec;11(1).

75. Tukwasibwe S, Tumwebaze P, Conrad M, Arinaitwe E, Kamya MR, Dorsey G, et al. Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda. Malar J. 2017 Mar 21;16.


Page 35 of 42

76. Rosenthal PJ. The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol. 2013;89(6):1025–38.

77. Okell LC, Reiter LM, Ebbe LS, Baraka V, Bisanzio D, Watson OJ, et al. Emerging implications of policies on malaria treatment: genetic changes in the Pfmdr-1 gene affecting susceptibility to artemether–lumefantrine and artesunate–amodiaquine in Africa. BMJ Glob Health. 2018 Oct 1;3(5):e000999.

78. Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia. Malar J. 2016 Dec;15(1):452.

79. Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The Role of Pfmdr1 and Pfcrt in Changing Chloroquine, Amodiaquine, Mefloquine and Lumefantrine Susceptibility in Western-Kenya P. falciparum Samples during 2008–2011. PLoS ONE. 2013 May 13;8(5).

80. Costa DC, Madureira AP, Amaral LC, Sanchez BAM, Gomes LT, Fontes CJF, et al. Submicroscopic malaria parasite carriage: how reproducible are polymerase chain reaction-based methods? Mem Inst Oswaldo Cruz. 2014 Feb;109(1):21–8.


Page 36 of 42

Annex

Appendix 1. Showing the remarkable decreasing community prevalences of asexual P.

falciparum parasitemia by microscopy or RDT; all age groups in May/June in two study

districts

Year

Micheweni district North A district

Tested Positive Positivity rates

(95% CI)

Tested Positive Positivity rates

(95% CI)

2003 1189 172 14.5% (12.5–16.6) 2167 174 8.0% (6.9–9.3)

2005 1241 135 10.9% (9.2–2.7) 1503 48 3.2% (2.4–4.2)

2006 1182 56 4.7% (3.6–6.1) 1433 12 0.8% (0.4–1.5)

2007 1575 15 1.0% (0.5–1.6) 1499 0 0.0% (0.0–0.2)

2008 2091 10 0.5% (0.2–0.9) 1746 4 0.2% (0.1–0.6)

2009 1539 0 0.0% (0–0.2) 1163 0 0.0% (0.0–0.3)

2011* 1271 10 0.8% (0.4–1.4) 1561 2 0.1% (0.0–0.5)

2013* 1579 7 0.4% (0.2–0.9) 1447 3 0.2% (0.0–0.6)

2015* 1515 9 0.6% (0.3–1.1) 1497 4 0.3% (0.1–0.7)

Note: *Malaria diagnosis by RDT instead of blood slide microscopy (Source: Björkman et al.

[6])


Page 37 of 42

Appendix 2. Implementation of malaria control tools/strategies in Zanzibar between 2002

and 2016

Year, month Interventions

2002,

November

New antimalarial treatment policy: ACT; 1st line: ASAQ, 2nd line: AL

2003,

September

ACT deployment in all public health facilities.

2004 ITN distribution, geographically focused Intermittent preventive treatment in

pregnancy (IPTp)

2005,

September

LLIN universal distribution to all children < 5 years and pregnant women

2006, July IRS (pyrethroid) aiming at annual universal coverage, in March before the main

transmission season (after 2006)

2006 RDT provision to all public health facilities. LLIN provision initiated to all pregnant

women and infants (9 months old) in MCH clinics

2008 LLIN universal distribution—two nets per household

2009 New antimalarial treatment policy: 1st line: ASAQ, 2nd line: quinine Weekly

reporting of malaria cases by mobile phone from health care facilities (MEEDS)

2012 LLIN universal distribution—two nets per household IRS policy change: targeting

hotspots only (carbamate 2012–2014, pirimiphos-methyl 2015-) Malaria case

investigation and reactive household RDT screening and LLIN distribution

2015 RDT and ACT provision to private health facilities (AMFm programme) Intermittent

screening and treatment in pregnancy (ISTp) replacing IPTp

2016 Larviciding in few selected sites New antimalarial treatment policy: ACT + PQ

(single low dose)

ACT artemisinin-based combination therapy, ASAQ artesunate-amodiaquine, AL- arthemeter-

lumefantrine, ITN - insecticide-treated net, IRS - indoor residual spraying, RDT - rapid

diagnostic test, LLIN - long-lasting insecticidal net, MEEDS - malaria early epidemic detection

system, AMFm - affordable medicines for malaria, MCH - mother and child health (Source:

Björkman et al. [6])


Page 38 of 42

Appendix 3. Definition of severe falciparum malaria1 severe manifestation of P. falciparum

malaria in adults and children

Clinical manifestations

• prostration,

• impaired consciousness,

• respiratory distress (metabolic acidosis),

• multiple convulsions,

• circulatory collapse,

• pulmonary edema (radiological),

• abnormal bleeding,

• jaundice,

• hemoglobinuria.

Laboratory findings

• severe anemia (hemoglobin < 5 g/dL, hematocrit < 15%),

• hypoglycemia (blood glucose < 2.2 mmol/l or 40 mg/dl),

• acidosis (plasma bicarbonate < 15 mmol/l),

• hyperlactatemia (venous lactic acid > 5 mmol/l),

• hypercarotenemia (> 4% in non-immune patients),

• renal impairment (serum creatinine above normal range for age).

Classification of severe malaria in children

Group 1: children at increased risk for death

• prostration

• respiratory distress

Group 2: children at risk for clinical deterioration

• hemoglobin < 5 g/dL, hematocrit < 15%

• two or more convulsions within 24 h

Group 3: children with persistent vomiting


Page 39 of 42

Appendix 4. Medications (with antimalarial activity) that should not be used during the

study period

List of medications

• chloroquine, amodiaquine;

• quinine, quinidine;

• mefloquine, halofantrine, lumefantrine;

• artemisinin and its derivatives (artemether, artether, artesunate, dihydroartemisinin);

• proguanil, chlorproguanil, pyrimethamine;

• sulfadoxine, sulfalene, sulfamethoxazole, dapsone;

• primaquine;

• atovaquone;

• antibiotics: tetracycline*, doxycycline, erythromycin, azythromycin, clindamycin,

rifampicin, trimethoprim;

• pentamidine.

* Tetracycline eye ointments can be used.


Page 40 of 42

Appendix 5. Patient discontinuation or protocol violation

Study patients who meet any of the following criteria will be classified as withdrawn.

• Withdrawal of consent. A patient may withdraw consent at any time, without prejudice

for further follow-up or treatment at the study site.

• Persistent vomiting of the treatment. A patient who vomits the study medication twice

will be withdrawn from the study and given rescue treatment.

• Failure to attend the scheduled visits during the first 3 days.

• Serious adverse events necessitating termination of treatment before the full course is

completed. A patient can be discontinued from the study if the principal investigator decides so

due to an adverse event of adequate nature or intensity. In this case, information on the adverse

event and symptomatic treatment given must be recorded on a case report form. If the adverse

event is serious, the principal investigator must notify the sponsor or its designee immediately

and follow the reporting procedures

• Enrolment violation:

• severe malaria on day 0; or

• erroneous inclusion of a patient who does not meet the inclusion criteria.

• voluntary protocol violation: self- or third-party administration of antimalarial drug (or

antibiotics with antimalarial activity) (Appendix 4)

• involuntary protocol violation:

• occurrence during follow-up of concomitant disease that would interfere with a clear

classification of the treatment outcome;

• detection of mono-infection with another malaria species during follow-up; or

• misclassification of a patient due to a laboratory error (parasitemia), leading to

administration of rescue treatment.

Patients who are withdrawn will be followed up until recovery or to the end of follow-up, no

treatment outcome will be assigned to these patients, and they will be censored or excluded from

the analysis. The reasons for discontinuation or protocol violation will be recorded on the case

report form.

treatment efficacy of artesunate-amodiaquine and...

Documents